DEVELOPMENT PROGRAMS
Clinical Pipeline Overview
Conjugated Psilocin Milestones Independent of Indication
API Synthesis
→
Phase 1 Safety Study
→
28-day Toxicity Rodent Study
→
Dose Frequency Anxiety Model
→
1st Psilocin Mucate Patent Oct 1, 2024
→
2nd Psilocin Mucate Patent Nov 11, 2024
→
FDA Required 2 animal tox
→
SAD
→
MAD
First Indication: Chronic Cluster Headache (CCH)
U.S. FDA Track
IND
XUS Foreign Regulatory
Second Application: Substance Use Disorder (SUD)
U.S. FDA Track
IND
XUS Foreign Regulatory
Preclinical Pharmacology
Third Application: Generalized Anxiety Disorder (GAD)
U.S. FDA Track
IND
XUS Foreign Regulatory
Preclinical Pharmacology
Sickle Cell Disease Medical Food and Therapeutic Programs
Altemia Medical Food
Rx Project S-100
Formulation Development
IND
Altemia®
Medical Food
Nutritional Support
Deficiency Related to Sickle Cell Disease
Market Ready
Learn About Our Companies
Explore our subsidiary companies advancing these therapeutic programs.